Clinical Trials Logo

Fatty Liver Disease clinical trials

View clinical trials related to Fatty Liver Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06302049 Not yet recruiting - Fatty Liver Disease Clinical Trials

Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis

Start date: May 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to test the implication of esomeprazole as a possible potential therapy for patients with NASH through evaluating its effect on ultrasound and fibrosis risk scores, serum levels of liver fibrosis biomarkers (fibronectin 1), insulin resistance, metabolic and inflammatory parameters.

NCT ID: NCT06071923 Not yet recruiting - Fatty Liver Disease Clinical Trials

Effect of Thyroid Disorders in Liver Diseases

Start date: January 1, 2024
Phase:
Study type: Observational

Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3. To detect early liver disorders in thyroid disorders using fibroscan .

NCT ID: NCT05966025 Not yet recruiting - Fatty Liver Clinical Trials

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

MAFLD
Start date: December 28, 2023
Phase: Phase 2
Study type: Interventional

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

NCT ID: NCT04191044 Not yet recruiting - Fatty Liver Disease Clinical Trials

Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)

THESIS
Start date: January 10, 2020
Phase:
Study type: Observational

Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment. Preliminary data suggest that portal hypertension may exist in the initial phases of NAFLD due to mechanisms that have not yet been elucidated. The clinical relevance of its development in these initial phases is unknown, while in more advanced phases new data are required to confirm the close relationship between portal hypertension and the risk of decompensation described in other etiologies. Likewise, the influence of fibrosis and portal hypertension on the cardiovascular risk of patients with NAFLD is unknown. The aim of the present multicenter project is to characterize the presence of portal hypertension and the mechanisms involved in its development in the different stages of NAFLD, to assess the association between the degree of portal hypertension and the development of portal hypertension-related complications, to know the early cardiovascular risk in the different stages of the disease, and to identify noninvasive biomarkers of the presence and severity of portal hypertension.